{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T01:17:33Z","timestamp":1724462253223},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T00:00:00Z","timestamp":1458604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:p>Biosimilars are increasingly being licensed as equipotent drugs, although efficacy and safety data are not available for all clinical indications. Accordingly, the efficacy of the biosimilar filgrastim Zarzio\u00ae combined with vinorelbine for chemo\u2010mobilization of CD34+ hematopoietic progenitor cells (HPC) in patients with multiple myeloma has not been evaluated yet. We compared the efficacy of vinorelbine combined with this biosimilar filgrastim for HPC mobilization to vinorelbine plus original filgrastim (Neupogen\u00ae). Overall, 105 multiple myeloma patients received vinorelbine 35 mg\/m<jats:sup>2<\/jats:sup> intravenously on day 1 and either original filgrastim (<jats:italic>n<\/jats:italic>\u2009=\u200961;58%) or biosimilar filgrastim (<jats:italic>n<\/jats:italic>\u2009=\u200944;42%) at a dose of 5 \u00b5g per kg body weight (BW) twice daily subcutaneously starting day 4 until the end of the collection procedure. Leukapheresis was scheduled to start on day 8 and performed for a maximum of three consecutive days until at least 4 \u00d7 10<jats:sup>6<\/jats:sup> HPC\/kg BW were collected. All patients proceeded to leukapheresis. In 102 (97%) patients the leukapheresis sessions were started as planned at day 8. The median number of collected HPC was 7.3 \u00d7 10<jats:sup>6<\/jats:sup>\/kg BW (0.2\u201318.3) with original filgrastim compared to 9 \u00d7 10<jats:sup>6<\/jats:sup>\/kg BW (4.2\u201023.8) with the biosimilar filgrastim (<jats:italic>P<\/jats:italic>\u2009=\u20090.16). HPC collection was successful in 57 (93%) of 61 patients of the original group and in all 44 (100%) patients of the biosimilar group (<jats:italic>P<\/jats:italic>\u2009=\u20090.14). No differences were observed regarding side effects. Duration of neutrophil engraftment after autologous HPC transplantation was similar between the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.17). Biosimilar and original filgrastim achieve comparable results in combination with vinorelbine regarding HPC mobilization and transplantation outcome in multiple myeloma patients. J. Clin. Apheresis 32:21\u201326, 2017. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/jca.21459","type":"journal-article","created":{"date-parts":[[2016,3,22]],"date-time":"2016-03-22T13:05:16Z","timestamp":1458651916000},"page":"21-26","source":"Crossref","is-referenced-by-count":9,"title":["Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo\u2010mobilization with vinorelbine in multiple myeloma patients"],"prefix":"10.1002","volume":"32","author":[{"given":"Julia\u2010Tatjana","family":"Maul","sequence":"first","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Stenner\u2010Liewen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhardt","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Epidemiology, Biostatistics and Prevention Institute, University of Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Pfrommer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Petrausch","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Kiessling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Schanz","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayathri","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Hematology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Mischo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Taverna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Triemli City Hospital Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bargetzi","sequence":"additional","affiliation":[{"name":"Center of Oncology, Hematology and Transfusion Medicine, Cantonal Hospital Aarau  Aargau Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Stupp","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Renner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Hospital Zurich Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.9.3131"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053583"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-561985"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00273.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.52"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1547"},{"key":"e_1_2_6_10_1","first-page":"691","article-title":"Mobilization of peripheral blood progenitor cells with high\u2010dose cyclophosphamide (4 or 7 g\/m2) and granulocyte colony\u2010stimulating factor in patients with multiple myeloma","volume":"17","author":"Goldschmidt H","year":"1996","journal-title":"Bone marrow Transplant"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.005"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050398"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.020"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0009-1"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2013.09.005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0114-z"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2013.04.109"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.7752"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i07"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(99)00043-0"},{"key":"e_1_2_6_21_1","first-page":"w13791","article-title":"Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation","volume":"143","author":"Samaras P","year":"2013","journal-title":"Swiss Med Wkly"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21459","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21459","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:06:04Z","timestamp":1695513964000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1002\/jca.21459"],"URL":"https:\/\/doi.org\/10.1002\/jca.21459","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]}}}